September 28, 2011
Nippon Boehringer Ingelheim (NBI) has announced the latest midterm report on the results of early post-marketing phase vigilance on its novel anticoagulant Prazaxa (dabigatran). Of the deaths reported since the product was launched in March 2011, many cases were of...read more